MEDP
NASDAQMedpace Holdings Inc.
News · 26 weeks59+44%
2026-04-192026-10-11
Mix3690d
- Insider26(72%)
- SEC Filings5(14%)
- Earnings2(6%)
- Leadership1(3%)
- Other1(3%)
- Analyst1(3%)
Latest news
25 items- INSIDERSEC Form 4 filed by Medpace Holdings Inc.4 - Medpace Holdings, Inc. (0001668397) (Issuer)
- INSIDERSEC Form 4 filed by Medpace Holdings Inc.4 - Medpace Holdings, Inc. (0001668397) (Issuer)
- INSIDERDirector Mccarthy Cornelius P. Iii converted options into 28 shares, increasing direct ownership by 0.23% to 12,303 units (SEC Form 4)4 - Medpace Holdings, Inc. (0001668397) (Issuer)
- INSIDERDirector Kraft Robert O. converted options into 32 shares, increasing direct ownership by 3% to 987 units (SEC Form 4)4 - Medpace Holdings, Inc. (0001668397) (Issuer)
- INSIDERDirector Carley Brian T converted options into 36 shares, increasing direct ownership by 0.13% to 27,861 units (SEC Form 4)4 - Medpace Holdings, Inc. (0001668397) (Issuer)
- INSIDERPresident & CEO Troendle August J. sold $30,320,929 worth of shares (48,667 units at $623.03), decreasing direct ownership by 13% to 338,225 units (SEC Form 4)4 - Medpace Holdings, Inc. (0001668397) (Issuer)
- ANALYSTUBS resumed coverage on Medpace with a new price targetUBS resumed coverage of Medpace with a rating of Neutral and set a new price target of $673.00
- INSIDERPresident & CEO Troendle August J. sold $1,589,941 worth of shares (2,564 units at $620.10), decreasing direct ownership by 0.66% to 386,892 units (SEC Form 4)4 - Medpace Holdings, Inc. (0001668397) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13D/A filed by Medpace Holdings Inc.SCHEDULE 13D/A - Medpace Holdings, Inc. (0001668397) (Subject)
- INSIDERPresident & CEO Troendle August J. sold $27,403,895 worth of shares (43,916 units at $624.01), decreasing direct ownership by 10% to 389,456 units (SEC Form 4)4 - Medpace Holdings, Inc. (0001668397) (Issuer)
- INSIDERPresident & CEO Troendle August J. sold $44,428,151 worth of shares (70,901 units at $626.62), decreasing direct ownership by 14% to 433,372 units (SEC Form 4)4 - Medpace Holdings, Inc. (0001668397) (Issuer)
- PRMedpace Holdings, Inc. to Report Third Quarter 2026 Financial Results on October 21, 2026Medpace Holdings, Inc. (NASDAQ:MEDP) ("Medpace") today announced that it will report its third quarter 2026 financial results after the market close on Wednesday, October 21, 2026. The Company will host a conference call the following morning, Thursday, October 22, 2026, at 9:00 a.m. ET to discuss these results. To participate in the conference call, interested parties must register in advance by clicking on this link. While it is not required, it is recommended you join 10 minutes prior to the event start. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique PIN that can
- INSIDERPresident & CEO Troendle August J. sold $6,749,952 worth of shares (10,880 units at $620.40), decreasing direct ownership by 2% to 504,273 units (SEC Form 4)4 - Medpace Holdings, Inc. (0001668397) (Issuer)
- INSIDERPresident & CEO Troendle August J. sold $15,364,149 worth of shares (24,741 units at $621.00), decreasing direct ownership by 5% to 515,153 units (SEC Form 4)4 - Medpace Holdings, Inc. (0001668397) (Issuer)
- INSIDERExec. VP, Operations Burwig Susan E exercised 3,000 shares at a strike of $166.73, increasing direct ownership by 5% to 65,984 units (SEC Form 4)4 - Medpace Holdings, Inc. (0001668397) (Issuer)
- INSIDERPresident & CEO Troendle August J. sold $403,176 worth of shares (650 units at $620.27), decreasing direct ownership by 0.12% to 539,894 units (SEC Form 4)4 - Medpace Holdings, Inc. (0001668397) (Issuer)
- PRInnventure Announces Board Leadership Changes to Further Enhance Board Independence and Acceleration of CEO TransitionBruce Brown Appointed as Chairman of the Innventure Board Catriona Fallon Publicly Named as Audit Committee Chair Dr. William Grieco Assumes CEO and Director Roles Effective September 1, 2026 Announces Ongoing Search for New Chief Financial Officer ORLANDO, Fla., Aug. 31, 2026 (GLOBE NEWSWIRE) -- Innventure, Inc. (NASDAQ:INV) ("Innventure" or the "Company"), an industrial growth conglomerate, today announces the appointment of Lead Independent Director Bruce Brown as independent Chairman of the Board, succeeding Michael Otworth, and the prior appointment of Independent Director Catriona Fallon as Audit Committee Chair. Innventure also announces the assumption by Dr. William Grieco of t
- INSIDERDirector Kraft Robert O. exercised 3,858 shares at a strike of $84.36 and sold $2,383,511 worth of shares (3,858 units at $617.81) (SEC Form 4)4 - Medpace Holdings, Inc. (0001668397) (Issuer)
- INSIDERPresident & CEO Troendle August J. sold $2,897,636 worth of shares (4,673 units at $620.08), decreasing direct ownership by 0.86% to 540,544 units (SEC Form 4)4 - Medpace Holdings, Inc. (0001668397) (Issuer)
- SECSEC Form 144 filed by Medpace Holdings Inc.144 - Medpace Holdings, Inc. (0001668397) (Subject)
- INSIDERPresident & CEO Troendle August J. sold $9,969,094 worth of shares (15,978 units at $623.93), decreasing direct ownership by 3% to 545,217 units (SEC Form 4)4 - Medpace Holdings, Inc. (0001668397) (Issuer)
- INSIDERCFO & Treasurer Brady Kevin M. exercised 3,400 shares at a strike of $138.87 and sold $2,125,816 worth of shares (3,400 units at $625.24) (SEC Form 4)4 - Medpace Holdings, Inc. (0001668397) (Issuer)
- INSIDERPresident & CEO Troendle August J. sold $26,281,390 worth of shares (42,783 units at $614.30), decreasing direct ownership by 7% to 561,195 units (SEC Form 4)4 - Medpace Holdings, Inc. (0001668397) (Issuer)
- INSIDERDirector Carley Brian T sold $3,043,150 worth of shares (5,000 units at $608.63), decreasing direct ownership by 15% to 27,825 units (SEC Form 4)4 - Medpace Holdings, Inc. (0001668397) (Issuer)
- INSIDERDirector Davenport Fred B Jr exercised 7,583 shares at a strike of $116.08 and sold $4,414,590 worth of shares (7,283 units at $606.15), increasing direct ownership by 9% to 3,798 units (SEC Form 4)4 - Medpace Holdings, Inc. (0001668397) (Issuer)
MEDP FAQ
7 questionsWhat does Medpace Holdings Inc. do?
Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It also provides clinical development services to the biotechnology, pharmaceutical, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and...Where does MEDP stock trade?
Medpace Holdings Inc. (MEDP) is listed on NASDAQ.What sector and industry is MEDP in?
Medpace Holdings Inc. operates in the Health Care sector, Biotechnology: Commercial Physical & Biological Resarch industry.When did Medpace Holdings Inc. go public?
Medpace Holdings Inc. (MEDP) completed its IPO in 2016.What are analysts saying about MEDP?
Medpace Holdings Inc. has had 8 recent analyst actions on file. The most recent action was from UBS: Neutral on 2026-09-30.What companies are similar to MEDP?
Notable peers in the same industry include IQV (IQVIA Holdings Inc.), INCY (Incyte Corp.), PPD (PPD, Inc.), CRL (Charles River Laboratories International Inc.), ICLR (ICON plc). Compare MEDP side-by-side with any of them on Quantisnow.How can I track MEDP on Quantisnow?
Quantisnow aggregates Medpace Holdings Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow MEDP to receive live email and push alerts on every new disclosure.